- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
[A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B]
[Article in Chinese]
J D Jia 1 , J Q Niu 2 , H You 1 , Y Y Kong 3 , J L Hou 3
Affiliations
Affiliations
1
Liver Research Center, Beijing Friendship Hospital, Capital Medical University; Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing 100050, China.
2
Department of Hepatology & Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun 130021, China.
3
Clinical Epidemiology & EBM Unit, National Clinical Research Center for Digestive Diseases; Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
PMID: 33685074 DOI: 10.3760/cma.j.cn501113-20210201-00055
Abstract in English, Chinese
长期口服抗病毒治疗可以有效抑制HBV DNA复制从而阻断和延缓进展为肝硬化和肝细胞癌,基于干扰素的治疗可以在部分患者实现持续病毒学应答,在少部分患者甚至可以达到HBsAg消失。目前国内外以慢性乙型肝炎临床治愈(HBsAg消失)为目标新药包括:口服核心蛋白抑制剂,耐受性和安全性良好,能有效降低HBV DNA和HBV RNA,但单用不能有效降低HBsAg水平;注射用干扰RNA或反义RNA,可以有效地降低HBsAg水平,且持续时间较长;免疫调节剂只能带来轻微的HBsAg水平下降,但同时也可能带来免疫相关的不良事件。在不远的将来,通过设计新颖的临床试验,探索不同机制的抗HBV新药联合或序贯应用,有可能实现慢性乙型肝炎的临床治愈。.
Keywords: Antiviral therapy; Clinical trial; Functional cure; Hepatitis B.
|
|